BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform

Reuters

Feb 18

Feb 18 (Reuters) - CervoMed Inc CRVO.O:

CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS
CERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026
CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEAR

Source text: ID:nGNX2TdN7K

Further company coverage: CRVO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612417996"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612417996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612417996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612417996","market":"fut","top_or_hot":-1,"title":"BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform </title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Inc <span>CRVO.O</span>:</p><ul><li><p>CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS</p></li><li><p>CERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026</p></li><li><p>CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEAR</p></li></ul><p>Source text: <span>ID:nGNX2TdN7K</span></p><p>Further company coverage: <span>CRVO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform </title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Inc <span>CRVO.O</span>:</p><ul><li><p>CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS</p></li><li><p>CERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026</p></li><li><p>CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEAR</p></li></ul><p>Source text: <span>ID:nGNX2TdN7K</span></p><p>Further company coverage: <span>CRVO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nFWN3ZD1D1:1","article_id":"2612417996","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612417996","pubTimestamp":1771413035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform Feb 18 (Reuters) - CervoMed Inc CRVO.O:CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRVO":"CervoMed"},"translate_title":"简介-Cervomed的Neflamapimod入选英国专家Als平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":0.9},"content_text":"BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform Feb 18 (Reuters) - CervoMed Inc CRVO.O:CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSISCERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEARSource text: ID:nGNX2TdN7KFurther company coverage: CRVO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}